A few years later Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children

作者：Vemer Pepijn^*; Postma Maarten J

来源：Human Vaccines & Immunotherapeutics, 2014, 10(7): 1841-1849.

DOI：10.4161/hv.29008

• Pneumococcal
• cost-effectiveness
• vaccines
• infant vaccination
• Netherlands
• PCV

This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICECER) of PCV13 over PCV10. Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of (sic)11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICECER of PCV13 compared with PCV10 was below (sic)30000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below (sic)2.63 per dose.

• 出版日期2014-7